PL4126854T3 - Sposób wytwarzania inhibitorów ferroportyny - Google Patents
Sposób wytwarzania inhibitorów ferroportynyInfo
- Publication number
- PL4126854T3 PL4126854T3 PL21712874.3T PL21712874T PL4126854T3 PL 4126854 T3 PL4126854 T3 PL 4126854T3 PL 21712874 T PL21712874 T PL 21712874T PL 4126854 T3 PL4126854 T3 PL 4126854T3
- Authority
- PL
- Poland
- Prior art keywords
- manufacturing
- ferroportin inhibitors
- ferroportin
- inhibitors
- manufacturing ferroportin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20165358 | 2020-03-24 | ||
| PCT/EP2021/057424 WO2021191202A1 (en) | 2020-03-24 | 2021-03-23 | Process for the production of ferroportin inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4126854T3 true PL4126854T3 (pl) | 2026-03-30 |
Family
ID=69960480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21712874.3T PL4126854T3 (pl) | 2020-03-24 | 2021-03-23 | Sposób wytwarzania inhibitorów ferroportyny |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230212159A1 (pl) |
| EP (2) | EP4681712A3 (pl) |
| JP (2) | JP7726905B2 (pl) |
| KR (1) | KR20220157395A (pl) |
| AU (1) | AU2021243494A1 (pl) |
| CA (1) | CA3172806A1 (pl) |
| ES (1) | ES3056168T3 (pl) |
| IL (1) | IL296653A (pl) |
| PL (1) | PL4126854T3 (pl) |
| WO (1) | WO2021191202A1 (pl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202304896A (zh) | 2021-04-22 | 2023-02-01 | 瑞士商威佛（國際）股份有限公司 | 經修飾的膜鐵運輸蛋白(ferroportin)抑制劑 |
| EP4405354A1 (en) | 2021-09-21 | 2024-07-31 | Vifor (International) Ltd. | N-substituted ferroportin inhibitors |
| JP2025535398A (ja) | 2022-10-21 | 2025-10-24 | ビフォー （インターナショナル） エージー | 二環式フェロポーチン阻害剤 |
| EP4731218A1 (en) | 2023-06-26 | 2026-04-29 | Vifor (International) AG | Ferroportin-inhibitors for the use in the treatment of hereditary haemochromatosis (hh) |
| WO2026041650A1 (en) | 2024-08-20 | 2026-02-26 | Vifor (International) Ag | Ferroportin-inhibitors for the use in the treatment of lupus nephritis |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6933308B2 (en) | 2002-12-20 | 2005-08-23 | Bristol-Myers Squibb Company | Aminoalkyl thiazole derivatives as KCNQ modulators |
| TW201111379A (en) | 2009-09-09 | 2011-04-01 | Vifor Int Ag | Novel thiazole-and oxazole-hepcidine-antagonists |
| WO2016065583A1 (en) | 2014-10-30 | 2016-05-06 | Merck Sharp & Dohme Corp. | Oxazole orexin receptor antagonists |
| CA3002416C (en) | 2015-10-23 | 2023-10-24 | Vifor (International) Ag | Benzimidazolyl derivatives for use as ferroportin inhibitors |
| JOP20180036A1 (ar) | 2017-04-18 | 2019-01-30 | Vifor Int Ag | أملاح لمثبطات فروبورتين جديدة |
-
2021
- 2021-03-23 EP EP25210767.7A patent/EP4681712A3/en active Pending
- 2021-03-23 WO PCT/EP2021/057424 patent/WO2021191202A1/en not_active Ceased
- 2021-03-23 JP JP2022557703A patent/JP7726905B2/ja active Active
- 2021-03-23 AU AU2021243494A patent/AU2021243494A1/en active Pending
- 2021-03-23 IL IL296653A patent/IL296653A/en unknown
- 2021-03-23 KR KR1020227032506A patent/KR20220157395A/ko active Pending
- 2021-03-23 ES ES21712874T patent/ES3056168T3/es active Active
- 2021-03-23 EP EP21712874.3A patent/EP4126854B1/en active Active
- 2021-03-23 PL PL21712874.3T patent/PL4126854T3/pl unknown
- 2021-03-23 US US17/913,631 patent/US20230212159A1/en active Pending
- 2021-03-23 CA CA3172806A patent/CA3172806A1/en active Pending
-
2025
- 2025-08-07 JP JP2025131977A patent/JP2025166080A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115362154A (zh) | 2022-11-18 |
| JP2025166080A (ja) | 2025-11-05 |
| IL296653A (en) | 2022-11-01 |
| EP4126854B1 (en) | 2025-12-03 |
| EP4126854A1 (en) | 2023-02-08 |
| ES3056168T3 (en) | 2026-02-18 |
| AU2021243494A1 (en) | 2022-08-25 |
| JP2023533889A (ja) | 2023-08-07 |
| CA3172806A1 (en) | 2021-09-30 |
| WO2021191202A1 (en) | 2021-09-30 |
| JP7726905B2 (ja) | 2025-08-20 |
| EP4126854C0 (en) | 2025-12-03 |
| KR20220157395A (ko) | 2022-11-29 |
| EP4681712A2 (en) | 2026-01-21 |
| EP4681712A3 (en) | 2026-04-22 |
| US20230212159A1 (en) | 2023-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL4126854T3 (pl) | Sposób wytwarzania inhibitorów ferroportyny | |
| IL314033A (en) | Ras inhibitors | |
| IL287940A (en) | Fgfr inhibitors and methods of use thereof | |
| IL311840A (en) | Ras inhibitors | |
| PL4063374T3 (pl) | Sposób wytwarzania l-glufosynatu | |
| EP4216951A4 (en) | KRAS G12D INHIBITORS | |
| IL284640A (en) | Pcsk9 inhibitors and methods of use thereof | |
| DK4337652T3 (da) | NLRP3-hæmmere | |
| IL283592A (en) | Inhibitors of apol1 and methods of using same | |
| EP4197538A4 (en) | Egfr inhibitor | |
| IL284661A (en) | Pcsk9 inhibitors and methods of use thereof | |
| DK4146348T3 (da) | Inhibitorer af nek7-kinase | |
| IL287751A (en) | Kcnt1 inhibitors and methods of use | |
| IL287768A (en) | Kcnt1 inhibitors and methods of use | |
| IL315027A (en) | Inhibitors of nlrp3 | |
| PL3781563T3 (pl) | Inhibitory HPK1, sposób ich wytwarzania oraz ich zastosowanie | |
| PL4046129T3 (pl) | Sposób wytwarzania | |
| LT4157831T (lt) | Jak1 inhibitoriaus gamybos būdas | |
| PL3942107T3 (pl) | Sposób wytwarzania | |
| IL292860A (en) | Allosteric egfr inhibitors and methods of use thereof | |
| IL286485A (en) | Pi4-kinase inhibitors and methods of using the same | |
| IL288851A (en) | Heteroaromatic inhibitors of astacin proteinases | |
| IL299700A (en) | Kcnt1 inhibitors and methods of use | |
| EP4333821A4 (en) | SARS-COV-2 INHIBITORS | |
| EP4247372A4 (en) | PLASMA KALLICREIN INHIBITORS |